TSHATaysha Gene Therapies, Inc.

TSHA Stock Price, Valuation & Chart | Taysha Gene Therapies, Inc.

Compare

$5.640-0.06 (-1.05%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology TSHA intrinsic value TSHA calculated fair value vs price

Overview Financials Dividends Ratios

TSHA Historical price chart

TSHA Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.80B

PE Ratio-13.43

EPS-0.42

Trading Volume1.99M

Today's High/Low5.96/5.55

Dividend Yield0.00

52 Week High/Low7.3/2.71

Shares Outstanding319.86M

TSHA Financial Statement

TSHA Analyst ratings

TSHA Analysis & performance metrics

TSHA Company profile

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic…

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for…

TSHA Management team

Name

Position

Sukumar Nagendran M.D.CTO

President, Head of Research & Development and Director

Kamran Alam CPA, M.B.A.CFO

Chief Financial Officer & Corporate Secretary

Hayleigh CollinsCTO

Director of Corporate Communications & Investor Relations

Emily McGinnis M.P.H.

Chief Patient & External Affairs Officer

Sean McAuliffe

Chief Business Officer

Sean P. NolanCEO

Chief Executive Officer & Chairman

Tracy M. Porter SPHR

Chief People Officer

Frederick Porter Ph.D.

Chief of Staff & Technical Operations Officer

Name

Position

Sukumar Nagendran M.D.CTO

President, Head of Research & Development and Director

Kamran Alam CPA, M.B.A.CFO

Chief Financial Officer & Corporate Secretary

Hayleigh CollinsCTO

Director of Corporate Communications & Investor Relations

Emily McGinnis M.P.H.

Chief Patient & External Affairs Officer

Sean McAuliffe

Chief Business Officer

Sean P. NolanCEO

Chief Executive Officer & Chairman

Tracy M. Porter SPHR

Chief People Officer

Frederick Porter Ph.D.

Chief of Staff & Technical Operations Officer

Management Team

Sukumar Nagendran M.D.CTO

President, Head of Research & Development and Director

Kamran Alam CPA, M.B.A.CFO

Chief Financial Officer & Corporate Secretary

Hayleigh CollinsCTO

Director of Corporate Communications & Investor Relations

Emily McGinnis M.P.H.

Chief Patient & External Affairs Officer

Sean McAuliffe

Chief Business Officer

Sean P. NolanCEO

Chief Executive Officer & Chairman

Tracy M. Porter SPHR

Chief People Officer

Frederick Porter Ph.D.

Chief of Staff & Technical Operations Officer

Management

Sukumar Nagendran M.D.CTO

President, Head of Research & Development and Director

Kamran Alam CPA, M.B.A.CFO

Chief Financial Officer & Corporate Secretary

Hayleigh CollinsCTO

Director of Corporate Communications & Investor Relations

Emily McGinnis M.P.H.

Chief Patient & External Affairs Officer

Sean McAuliffe

Chief Business Officer

Sean P. NolanCEO

Chief Executive Officer & Chairman

Tracy M. Porter SPHR

Chief People Officer

Frederick Porter Ph.D.

Chief of Staff & Technical Operations Officer

Total 8 executives

TSHA Frequently asked questions

What is Taysha Gene Therapies, Inc. (TSHA) Stock Price?

Current stock price of Taysha Gene Therapies, Inc. (TSHA) stock is $5.640. The stock price is -1.05% lower in the session. The intraday range can be seen from this page. Volume of Taysha Gene Therapies, Inc. (TSHA) stock is 1.99M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Taysha Gene Therapies, Inc. (TSHA) stock price going up or down today?

The stock price of Taysha Gene Therapies, Inc. (TSHA) can change with earnings, company news, and overall market sentiment. Taysha Gene Therapies, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Taysha Gene Therapies, Inc. stock expensive at its current price?

Whether Taysha Gene Therapies, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for TSHA on this page is -13.43. EPS on this page is -0.42. Compare those figures with peers and growth expectations before deciding if the current Taysha Gene Therapies, Inc. price is justified.

How has the stock price of Taysha Gene Therapies, Inc. (TSHA) performed historically?

Historical performance for Taysha Gene Therapies, Inc. (TSHA) is shown on the price chart on this page. Review multi-period moves alongside volume to see how TSHA reacted to past earnings and market events.

Should I buy Taysha Gene Therapies, Inc. (TSHA) stock, at this price?

Buying Taysha Gene Therapies, Inc. (TSHA) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.